Blood test may unlock secrets of lung cancer drug resistance
NCT ID NCT04087473
First seen May 16, 2026 · Last updated May 19, 2026 · Updated 1 time
Summary
This study looked at blood samples from 50 people with a specific type of lung cancer (ALK-positive) that had stopped responding to targeted treatments. The goal was to find genetic changes in the blood that explain why the drugs stopped working. By matching these changes to the right next treatment, doctors hope to improve outcomes for patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Centre
Seoul, 05505, South Korea
-
National Cancer Center Singapore
Singapore, 169690, Singapore
-
Seoul National University Hospital
Seoul, South Korea
-
The Chinese University of Hong Kong
Hong Kong, Hong Kong
-
University Malaya Medical Centre
Kuala Lumpur, Malaysia
Conditions
Explore the condition pages connected to this study.